SCHEMBL11975940

SCHEMBL11975940

CCOC(=O)[C@@]12C[C@H]1/C=C\CCCCC[C@H](C)C(=O)N1CCC[C@H]1C(=O)N2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 3/20 0.33
▸ HDAC1 Q13547 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ HSD17B10 Q99714 3/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ ALDH1A1 P00352 4/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ USP2 O75604 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ PARP1 P09874 2/20 0.31
▸ CHEK1 O14757 1/20 0.31
▸ MAP2K1 Q02750 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ ADRB3 P13945 1/20 0.31
▸ ADRA2B P18089 1/20 0.31
▸ ADRA2C P18825 1/20 0.31
▸ TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8249373 0.90 DPP4 (0.37) HDAC4HDAC1GAAHSD17B10ALOX15
SCHEMBL15491749 0.90 ADRB3 (0.31) POLBADRB3ADRA2BADRA2C
SCHEMBL12730861 0.87 ADRB3 (0.34) ADRB3ADRA2BADRA2C
SCHEMBL11975703 0.87 ADRB3 (0.34) ADRB3ADRA2BADRA2C
SCHEMBL11975943 0.87 ADRB3 (0.35) HDAC4HDAC1GAAHSD17B10ALOX15
SCHEMBL16938902 0.86 HDAC4 (0.32) HDAC4HDAC1POLBMEN1KMT2A
SCHEMBL1683122 0.85 ADRB3 (0.36) GAAHSD17B10ALOX15ALDH1A1KDM4E
SCHEMBL13059221 0.85 ADRB3 (0.36) GAAHSD17B10ALOX15ALDH1A1KDM4E
SCHEMBL8172602 0.85 ADRB3 (0.34) GAAHSD17B10ALOX15ALDH1A1KDM4E
SCHEMBL1645088 0.85 ADRB3 (0.36) GAAHSD17B10ALOX15ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299021-B2 Macrocyclic inhibitors of hepatitis C virus replication INTERMUNE, INC. (US) 2012-10-30 — — US disclosed
US-20120208995-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION ARRAY BIOPHARMA, INC. (US) 2012-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208995-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS HDAC4 2076/4885HDAC1 783/4885GAA 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback